<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176604</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0770</org_study_id>
    <secondary_id>NCI-2018-01816</secondary_id>
    <secondary_id>2008-0770</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01176604</nct_id>
  </id_info>
  <brief_title>Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>Protocol for Use of TheraSphereÂ® for Treatment of Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well yttrium Y 90 glass microspheres work in treating patients with&#xD;
      hepatocellular carcinoma that cannot be removed by surgery. Radioactive drugs, such as&#xD;
      yttrium Y 90 glass microspheres, may carry radiation directly to cancer cells and not harm&#xD;
      normal cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Provide oversight to treatment with yttrium Y 90 glass microspheres (TheraSphere) to&#xD;
      eligible patients with hepatocellular carcinoma (HCC) of the liver who are not surgical&#xD;
      resection candidates.&#xD;
&#xD;
      II. Evaluate patient experience, toxicities and overall survival associated with TheraSphere&#xD;
      treatment.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive yttrium Y 90 glass microspheres via a catheter over 5 minutes on day 0.&#xD;
      Patients may receive additional treatments at 4-12 week intervals until all tumors in the&#xD;
      liver have been treated in the absence of disease progression or unaccepted toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 3-6 weeks, then annually for&#xD;
      up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2010</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oversight to treatment with yttrium Y 90 glass microspheres</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Associated with yttrium Y 90 glass microspheres treatment. Data analysis will be limited to descriptive reports of the number and characteristics of the patients treated and their clinical and adverse event experiences.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient experience</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Associated with yttrium Y 90 glass microspheres treatment. Data analysis will be limited to descriptive reports of the number and characteristics of the patients treated and their clinical and adverse event experiences.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>30 days after each treatment</time_frame>
    <description>Associated with yttrium Y 90 glass microspheres treatment. Data analysis will be limited to descriptive reports of the number and characteristics of the patients treated and their clinical and adverse event experiences.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Associated with yttrium Y 90 glass microspheres treatment. Data analysis will be limited to descriptive reports of the number and characteristics of the patients treated and their clinical and adverse event experiences.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">305</enrollment>
  <condition>Stage III Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IIIA Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IIIB Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IV Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IVA Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Stage IVB Hepatocellular Carcinoma AJCC v8</condition>
  <condition>Unresectable Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (yttrium Y 90 glass microspheres)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive yttrium Y 90 glass microspheres via a catheter over 5 minutes on day 0. Participants may receive additional treatments at 4-12 week intervals until all tumors in the liver have been treated in the absence of disease progression or unaccepted toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Yttrium Y 90 Glass Microspheres</intervention_name>
    <description>Given via catheter</description>
    <arm_group_label>Treatment (yttrium Y 90 glass microspheres)</arm_group_label>
    <other_name>TheraSphere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of unresectable intrahepatic HCC. The histopathology confirmation criterion&#xD;
             may be waived in patients with a radiographically identifiable liver mass, known&#xD;
             laboratory or clinical risk factors for cancer or elevated tumor markers such as&#xD;
             alphafetoprotein (AFP)^21 and clinical findings. Guidelines from the American&#xD;
             Association for the Study of Liver Diseases (AASLD) and the European Association for&#xD;
             the Study of the Liver (EASL) describe in detail the approach and algorithm for&#xD;
             diagnosing HCC&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status Score 0 - 2&#xD;
&#xD;
          -  Life expectancy &gt;= 3 months&#xD;
&#xD;
          -  &gt; 4 weeks since prior radiation, surgery or chemotherapy&#xD;
&#xD;
          -  Able to comprehend and provide written informed consent in accordance with&#xD;
             institutional and federal guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Within 15 days of treatment demonstrating liver dysfunction: Aspartate&#xD;
             aminotransferase (AST) (Serum Glutamic-Oxalocetic Transaminase - SGOT) or alanine&#xD;
             aminotransferase (ALT) (Serum Glutamic-Pyruvic Transaminase - SGPT) &gt; 5 times Upper&#xD;
             Normal Limit (UNL)&#xD;
&#xD;
          -  Within 15 days of treatment demonstrating liver dysfunction: Serum bilirubin &gt; 2.0&#xD;
             mg/dl (unless segmental infusion is planned)&#xD;
&#xD;
          -  Any contraindications to angiography and hepatic artery catheterization such as:&#xD;
             History of severe allergy or intolerance to any contrast media, narcotics, sedatives,&#xD;
             or atropine that cannot be corrected or premedicated; Bleeding diathesis, not&#xD;
             correctable by usual forms of therapy; Severe peripheral vascular disease that would&#xD;
             preclude catheterization&#xD;
&#xD;
          -  Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of&#xD;
             radiation to the lungs in a single treatment&#xD;
&#xD;
          -  Clinical evidence of pulmonary insufficiency&#xD;
&#xD;
          -  Evidence of any detectable Technetium-99 Macroaggregated Albumin (Tc-99m MAA) flow to&#xD;
             the stomach or duodenum, after application of established angiographic techniques to&#xD;
             stop or mitigate such flow&#xD;
&#xD;
          -  Complete occlusion of the main portal vein&#xD;
&#xD;
          -  Significant extrahepatic disease representing an imminent life-threatening outcome&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Significant underlying medical or psychiatric illness&#xD;
&#xD;
          -  Co-morbid disease of condition that would preclude safe delivery of TheraSphere&#xD;
             treatment or, in the judgment of the physician, place the patient at undue risk&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Tumor type demonstrated on imaging to be infiltrative, tumor volume &gt; 70% of the&#xD;
             target liver volume, or tumor nodules too numerous to count, or tumor volume &gt; 50%&#xD;
             combined with an albumin &lt; 3 g/dL, or complete occlusion of the main portal vein&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armeen Mahvash</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armeen Mahvash</last_name>
    <phone>713-563-7340</phone>
    <email>armeen.mahvash@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armeen Mahvash</last_name>
      <phone>713-563-7340</phone>
    </contact>
    <investigator>
      <last_name>Armeen Mahvash</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

